Upgolyv (golimumab injection)
/ JAMP Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 20, 2026
JAMP Pharma Group Strengthens Its Immunology Biosimilars Portfolio with PrUpgolyv, a Golimumab Biosimilar that has Receive its Notice of Compliance by Health Canada.
(Canada Newswire)
- "Pr Upgolyv increases access to high quality biosimilar therapies for Canadian patients living with chronic inflammatory autoimmune diseases...Patients prescribed Pr Upgolyv will be supported through the JAMP Care patient support program, offering access, education, and treatment assistance."
Canada approval • Ankylosing Spondylitis • Psoriatic Arthritis • Rheumatoid Arthritis
1 to 1
Of
1
Go to page
1